Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment

Paula Boaventura, Dina Pereira, Ricardo Celestino, Adélia Mendes, Tadao Nakasawa, José Teixeira-Gomes, Manuel Sobrinho-Simões and Paula Soares

1IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Dr Roberto Frias s/n, 4200-465 Porto, Portugal,
2Department of Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamashini, Yamashini, Japan,
3Department of Pathology and Oncology, Medical Faculty, University of Porto, Porto, Portugal and
4Department of Pathology, Hospital Centre of S. João, Porto, Portugal

(Correspondence should be addressed to P Boaventura; Email: mboaventura@ipatimup.pt)

Abstract

Objective: Exposure to ionizing radiation at young age is the strongest risk factor for the occurrence of papillary thyroid carcinoma (PTC). RET/PTC rearrangements are the most frequent genetic alterations associated with radiation-induced PTC, whereas BRAF and RAS mutations and PAX8–PPARG rearrangement have been associated with sporadic PTC. We decided to search for such genetic alterations in PTCs of patients subjected in childhood to scalp irradiation.

Design: We studied 67 thyroid tumors from 49 individuals irradiated in childhood for tinea capitis scalp epilation: 36 malignant (12 cases of conventional PTC (cPTC), two cPTC metastases, 20 cases of follicular variant PTC (FVPTC), one oncocytic variant of PTC and one follicular carcinoma) and 31 follicular thyroid adenomas.

Methods: The lesions were screened for the BRAFV600E and NRAS mutations and for RET/PTC and PAX8–PPARG rearrangements.

Results: BRAFV600E mutation was detected in seven of 14 (50%) cPTC and two of 20 FVPTC (10%) (P=0.019). NRAS mutation was present in one case of FVPTC (5%). RET/PTC1 rearrangement was found, by RT-PCR, in one of 17 cases (5.9%) and by fluorescence in situ hybridization in two of six cases (33%). PAX8–PPARG rearrangement was not detected in any carcinoma. None of the follicular adenomas presented any of the aforementioned genetic alterations.

Conclusions: The prevalence of BRAFV600E mutation in our series is the highest reported in series of PTCs arising in radiation-exposed individuals. The prevalence of RET/PTC1 rearrangement fits with the values recently described in a similar setting.

European Journal of Endocrinology 169 673–679

Introduction

Exposure to ionizing radiation at young age is known as the strongest risk factor for thyroid carcinoma development, namely papillary thyroid carcinoma (PTC) (1), which is the most frequent histotype representing 80% of all thyroid tumors. Thyroid is very sensitive to both external and internal radiation, being the only organ with a documented major rise in cancer incidence after radiation exposure, especially in childhood (2). However, the data on the effects of low-dose radiation remain limited (3).

X-ray scalp epilation for tinea capitis treatment, applying a mean average dose to the thyroid gland of 9.3 cGy (range 4.5–49.5 cGy), has shown to increase thyroid cancer risk (4). It is not yet known whether scalp radiation-associated thyroid cancers have the same genetic alterations and clinical behaviour as the sporadic thyroid cancers (5).

Four mutation types constitute the majority of known mutations in thyroid cancer and carry the highest impact on tumor diagnosis and prognosis: BRAF and RAS point mutations and RET/PTC and PAX8–PPARG rearrangements (6). It was advanced that the dominant mutation mechanism in radiation-induced tumors is chromosomal rearrangement, whereas point mutation is the most prevalent mechanism in sporadic tumors (1). In radiation-induced tumors, namely in post-Chernobyl PTCs, RET/PTC rearrangements can be detected in up to 84% of PTCs (1, 7, 8) and up to 52% of thyroid adenomas (7, 8, 9, 10), but some studies showed lower values, 34–51% (11, 12), and 43% in a population exposed to external radiation (10). In sporadic, non-irradiated thyroid tumors, RET/PTC rearrangement frequency can be as low as 5–15% (7). PAX8–PPARG fusion oncogene has been identified as more prevalent in follicular carcinoma (13), but was also found in 1–38% of cases of follicular variant of PTC.
(FVPTC) (14, 15, 16), and in 2–33% of cases of follicular adenoma (15, 16).

At variance with radiation–induced tumors, the most prevalent mechanism in sporadic tumors is point mutation, typically involving the BRAF and RAS genes (1). BRAF mutations occur in ~45–53% of adult sporadic PTCs (17, 18), being considered as rare events in subjects exposed to radiation in children, both internal and external, with frequencies ranging from 4 to 24% (12, 19, 20). Recently, however, Dinets et al. (11) reported a BRAF mutation prevalence of 37% in a recent study of post-Chernobyl cases. These authors also detected the co-occurrence of RET/PTC and BRAF mutation (11). In atomic bomb survivors, Hamatani et al. (21) found that RET/PTC rearrangement, and not BRAF mutations, were closely associated with radiation-associated adult-onset PTC.

RAS mutations have been detected in 10–20% of PTCs, virtually all belonging to the follicular variant (22) and in 20–40% of follicular adenomas (15). RAS can present three isoforms being the NRAS isoform predominantly mutated in thyroid tumors (23). No major difference has been associated with the radiation in comparison with the sporadic setting (24). Recently, Leeman-Neill et al. (25) reported an 8% prevalence of RAS mutations in a post-Chernobyl cohort.

The aim of this study was to evaluate the aforementioned genetic alterations in PTCs following X-ray external radiation performed in childhood to induce scalp epilation for tinea capitis treatment, a cohort in which we have already shown a high prevalence of thyroid cancer (26). As far as we know, only RET/PTC rearrangements have been studied in similar cohorts (10).

Subjects and methods

Cases

We have clinically observed 1287 individuals from an original cohort of 5356 individuals who had been submitted in childhood to scalp irradiation for tinea capitis treatment (26). Briefly, the standard treatment was done according to the Kienbock–Adamson technique (27) using one X-ray epilation session (325-400R); 6% of the 5356 individuals (n = 318) were submitted to two or three sessions (irradiation dose ≥ 630R) (26).

Thirty-five patients with thyroid cancer and 38 patients with follicular adenoma were identified. Sixty-seven thyroid tumors from 49 participants were retrieved from several pathology departments and laboratories and were histologically re-evaluated by two pathologists (M S-S and T N). Formalin-fixed and paraffin-embedded (FFPE) blocks from 24 of the 35 patients with thyroid carcinoma (69%) and from 28 of the 38 patients with follicular adenoma (74%) were examined. Some patients presented more than one lesion (n = 9), leading to a total of 36 thyroid carcinomas and 31 follicular adenomas.

All the procedures were performed under strict ethical and confidentiality procedures according to the Portuguese ethical rules. The study was approved by the Ethics Committee of the Hospital Pedro Hispano and all the patients signed an informed consent.

Identification of BRAF and NRAS mutations

Genomic DNA was extracted from microdissected FFPE pathological tissue, using 10 μm sections, by conventional overnight incubation with proteinase K. Subsequent DNA purification was performed using Invitrogen Spin Tissue Mini Kit (Invitrogen, Berlin, Germany) according to the manufacturer’s protocol.

The following specific PCR primers were used to flank the mutational hotspot region of BRAF activation segment (exon 15) and NRAS exon 2: forward primer for BRAF, 5′-TCATATAAGTTCTGCTGATAGGAG-3′ and the reverse primer, 5′-GCCCATAATTTAATCATGTCGTA-3′; for the NRAS exon 2 amplification, the forward primer used was 5′-GATCTTCAGACACACACAGT-3′ and the reverse was 5′-GAAATAATGTCTCCTAGTAC-3′. All the procedures, including automated sequencing, were performed as described previously (16).

Briefly, PCR amplifications were performed in a 25 μl volume reaction containing 25–100 ng genomic DNA, 200 μM each dNTP, 0.1 μg of each, forward and reverse, primer, 1× GoTaq Flexi Buffer (Promega), 2.5 mM MgCl2 and 0.75 U of Taq DNA polymerase (Promega). Reaction mixtures were submitted to 40 amplification cycles preceded by a Taq activation step at 95 °C for 5 min, each cycle comprised a denaturation step at 95 °C for 30 s, annealing at 58 °C for 40 s and extension at 72 °C for 45 s followed by a final extension at 72 °C for 10 min. PCR products were then purified using enzymatic digestion with Exonuclease I (Fermentas, Vilnius, Lithuania) and Shrimp Alkaline Phosphatase (Fermentas) and sequenced using an ABI Prism BigDye Terminator Cycle Sequencing Kit (Perkin–Elmer, Foster City, CA, USA) and an ABI Prism 377 DNA Sequencer (Perkin–Elmer). All the detected mutations were further validated by a new independent amplification and sequencing.

Identification of RET/PTC and PAX8–PPARG rearrangements

Total RNA was extracted from paraffin-embedded tissues using the RecoverAll Nucleic Acid Isolation Kit for FFPE (Ambion – Life Technologies, Foster City, CA, USA) according to the manufacturer’s instructions.

The cDNA was obtained using the RevertAid Reverse Transcriptase (Thermo Scientific, Waltham, MA, USA) at 37 °C for 60 min, followed by enzyme inactivation at 99 °C for 5 min. The PCR using cDNA was performed with HotStart Taq DNA polymerase kit (Qiagen Co.) and initiated by denaturation at 95 °C for 15 min followed.
by 30 cycles of 30 s at 95 °C, 75 s at 56–60 °C and 30 s at 72 °C, before a final elongation step at 72 °C for 6 min. The RT-PCR products were analyzed by 2% agarose gel electrophoresis. PCRs creating a visible band on the gel were sequenced directly (ABI 3730 DNA analyser; Applied Biosystems by Life Technologies). The housekeeping GAPDH gene was also amplified to control the cDNA integrity of the samples. Primers for cDNA amplification: RET–PTC1 rearrangement: 5′-GTCGGGGGCATTTGCTACT (CCDC6, exon 1), 3′-AAGTTCTTCCAGAGGAATGC (RET, exon 12). RET–PTC3 rearrangement: 5′-TGGAGAAGAGGCTGTATCT (NCOA4, exon 6); 3′-CTTTCAGCATCTCTCAGG (RET, exon 12). PAX8–PPARG rearrangements: PAX8–PPARG (F7): 5′-AACCCTCTCGACTCACCAGAC (PAX8, exon 7), 3′-TGGAGAAGAGGCTGTATCT (NCOA4, exon 6); 3′-CTTTCAGCATCTCTCAGG (RET, exon 12). PAX8–PPARG (F8): 5′-CCCTTCAATGCCTTTCCCC, 3′-TGGAGAAGAGGCTGTATCT (NCOA4, exon 6); 3′-CTTTCAGCATCTCTCAGG (RET, exon 12). PAX8–PPARG (F9): 5′-CTATGCTTCTCTGCCATC (PAX8, exon 9), 3′-TGGAGAAGAGGCTGTATCT (NCOA4, exon 6); 3′-CTTTCAGCATCTCTCAGG (RET, exon 12).

In addition to RT-PCR approach, fluorescence in situ hybridization (FISH) was performed in tumor samples in order to confirm the RET–PTC rearrangements. Briefly, isolated nuclei were extracted from 50 μm sections of FFPE thyroid tumor tissues. The isolation of nuclei from FFPE tissue and FISH technique was performed following the procedure described by Marques et al. (28). RET/PTC rearrangement detection was investigated with a DNA probe generated from three yeast artificial chromosome clones (313F4, 214H10, and 344H4) covering the RET locus (kindly provided by Prof. Horst Zitzelsberger); probe hybridization was performed as described (29). FISH signals were analyzed and recorded with a CytoVision System (Applied Imaging, New Castle, UK). For RET/PTC, at least 200 nuclei were scored for the presence of a split FISH signal (rearranged) in addition to an overlapping signal (normal). Only cells with either two overlapping signals or one split and one overlapping signal were counted to ensure that only intact nuclei had been scored. Only when 10% or more rearranged nuclei were present, we considered the case as positive for RET/PTC or PAX8-PPARG rearrangements (30).

Samples of thyroid cancer, positive for RET/PTC1 or RET/PTC3 rearrangements by RT-PCR and cDNA sequencing, were used as positive controls for FISH.

**Results**

**Histopathology**

All the lesions were observed and reclassified independently by two pathologists (M S-S and T N), being 36 malignant and 31 follicular adenomas. The malignant lesions included 12 conventional PTC (cPTC), 20 FVPTC, one oncocytic variant of PTC, two lymph node metastases of cPTC and one follicular carcinoma.

**BRAF and NRAS mutations**

The BRAF V600E mutation was detected in nine of 36 malignant lesions (25%), two cases of FVPTC (10%) (Fig. 1A) and seven of cPTC (50%) (Fig. 1B), this difference being significant (Table 1) (P = 0.019). In one case of cPTC, there was insufficient material from the tumor for further analysis.

There were no differences in the BRAF V600E mutation prevalence according to gender, age at irradiation, age at diagnosis, latency period (time between irradiation and surgery) nor any clinicopathological parameter, either considering tumors or individual patients. Only...
two thyroid cancer patients had been submitted to a higher irradiation dose, so it was not possible to evaluate the dose effect in the \( \text{BRAF}^{V600E} \) mutation prevalence. One of the 20 cases of FVPTC showed the rare \( \text{BRAF}^{V600E-1E} \) mutation, described by our group (31) (Fig. 2). None of the benign lesions – follicular adenomas – presented \( \text{BRAF} \) mutation. \( \text{NRAS} \) mutation was detected in only one case of FVPTC.

RET/PTC and PAX8–PPARG rearrangements

RNA was successfully recovered in 32 thyroid tumors (15 benign and 17 malignant). By RT-PCR, \( \text{RET/PTC1} \) rearrangement was detected in only one of 17 cases of thyroid cancer (5.9%), a case of cPTC (Figs 1C and 3). The \( \text{RET/PTC1} \) rearrangement was not identified in any of the follicular adenomas (n = 15).

All the carcinomas for which there was enough material for FISH study (n = 6) were evaluated by this assay. In two of six cases (33.3%), the \( \text{RET/PTC1} \) rearrangement was detected, confirming the case already observed by RT-PCR (Fig. 4). The other case detected by FISH was a case of a FVPTC. No PAX8–PPARG rearrangements were detected in any case. All the mutations/rearrangements were mutually exclusive.

Discussion

Almost all the carcinomas found in this series of childhood-irradiated individuals were PTCs (35/36, 97.2%). Radiation exposure has been described as significantly increasing the risk for thyroid malignancies, particularly PTC (32), in accordance with the results of the present series. We observed the FVPTC in 55.6% of the PTCs (20/36). In other series of PTCs, the prevalence of the FVPTC varied from 7 to 53% (33, 34, 35, 36, 37, 38), our frequency being similar to the higher value of this range, but no reports were found referring in particular the prevalence of FVPTC in the irradiation context. The high variation in the frequency of FVPTC observed can be due to different evaluation criteria adopted in the diverse studies published to date.

Our results show that the prevalence of \( \text{BRAF}^{V600E} \) mutation in our series is in the high range of that reported in PTCs of radiation-exposed individuals (internal or external) (4–24%) and lower than the values referred for sporadic PTCs (45–53%) (39). We found that the \( \text{BRAF}^{V600E} \) mutation was significantly more prevalent in the cPTC (50%) than in FVPTC (10%), in accordance with the 35–70 vs 5–20% reported by us and others for sporadic PTC (39, 40).

We did not find any significant difference regarding the prevalence of histological subtypes or presence of \( \text{BRAF} \) mutation according to age, gender, latency and clinicopathological parameters.

\( \text{RET/PTC1} \) rearrangement was detected in 6% of the thyroid carcinomas using RT-PCR (n = 17), but this value increased to 33% in the six cases in which it was possible to use FISH. FISH has been considered as the assay of choice for rearrangement detection, although its use in FFPE tissue is hampered by the quality of the material and size of the lesions. In fact, the technique is not feasible in small PTCs that represented part of the cases of our series. A prevalence of 33% may still be assumed as a low figure for this rearrangement in the context of thyroid irradiation, although the values reported in the literature have been decreasing recently. Dinets et al. (11) found a 29% prevalence for \( \text{RET/PTC1} \) rearrangement and a 6% prevalence for \( \text{RET/PTC3} \) rearrangement in a recent study of adult post-Chernobyl
PTC cases. The variation in the prevalence and specificity of RET/PTC rearrangements reported in different series can be due to differences in the prevalence of this alteration in specific age groups (15).

Nevertheless, Elisei et al. (9) reported that the presence of RET/PTC rearrangements was not higher in radiation-induced tumors compared with those naturally occurring, nor different after exposure to radioiodine or external radiation; it was also not dependent on age at irradiation. At variance with Elisei et al., other authors advanced that the prevalence of the different genetic alterations can vary with the time of latency of the tumors. In Chernobyl context, it was verified that the prevalence of RET/PTC in short latency period tumors (‘first wave’) was higher than in tumors that arise later (‘second wave’) (41). The tumors we have analysed in the present series have a long latency period (> 30 years).

By RT-PCR, the PAX8–PPARG rearrangement was not observed in any of the FVPTC of the present series. In a previous study, we have detected, by FISH, PAX8–PPARG rearrangement in 37.5% of sporadic cases of FVPTC (16). In another study of sporadic FVPTC, this rearrangement was undetectable by RT-PCR in all the seven cases studied (42). One limitation of this study was the fact that we had insufficient tumor material, due to small tumor size, to apply the FISH technique to most of our cases. The rearrangement was not detected in any follicular adenoma, in accordance with Dwight et al. (43) and differently from the 33% prevalence in sporadic follicular adenomas (16).

In conclusion, we report a thorough histological and genetic characterization of thyroid tumors arising, after a long latency period, in the context of low-dose external irradiation (scalp). We also report for the first time data on the prevalence of FVPTC in tinea capitis irradiation context, the results of the present series being slightly above the highest values reported in sporadic PTCs. Moreover, with the exception of RET/PTC rearrangements, the other common genetic alterations in thyroid cancer (BRAF and NRAS mutations and PAX8–PPARG rearrangements) had never been studied in this low-dose external radiation context. Further studies are needed, with larger series, in order to clarify, using FISH technique, the actual importance of these rearrangements when the thyroid is submitted to low-dose external radiation. This is important if we take into account that radiotherapy for head and neck cancers, thorax cancers, lymphomas, breast cancers and even all body irradiation may expose the thyroid to radiation due to its anatomical position (44).

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by grants from Calouste Gulbenkian Foundation (ref. 766-36) and Portuguese Foundation for Science and Technology (FCT) (project: PIC/IC/83154/2007) and by project ‘Microenvironment, metabolism and cancer’ partially supported by Programa Operacional Regional do Norte (ON.2 – O Novo Norte) under the Quadro de Referência Estratégico Nacional (QREN) and through the Fundo Europeu de Desenvolvimento Regional (FEDER) and additional funding from FCT grant to P Boaventura (SRH/BPD/34276/2007). IPATIMUP is an Associate Laboratory of the Portuguese Ministry of Science, Technology and Higher Education and is partially supported by FCT.

Acknowledgements

Gratefulness is also due to all the patients that agreed to participate in this study as well as to all the physicians that provided clinical information. Prize ACS-MERCK SERONO in Cancer Epidemiology, 2010.

References

2 Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones 2010 9 103–108.


37 Ertek S, Yilmaz NC, Cicero AF, Vurupalmaz O, Demiroz AS & Erdogan G. Increasing diagnosis of thyroid papillary carcinoma


Received 1 July 2013
Revised version received 19 August 2013
Accepted 21 August 2013